Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Tuesday. The firm issued a hold rating on the stock.

Separately, HC Wainwright restated a buy rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Thursday, May 9th.

Can-Fite BioPharma Trading Down 1.0 %

Can-Fite BioPharma stock opened at $2.84 on Tuesday. Can-Fite BioPharma has a 12 month low of $1.81 and a 12 month high of $4.48. The business’s 50 day simple moving average is $2.38 and its 200 day simple moving average is $2.21. The company has a market cap of $10.05 million, a price-to-earnings ratio of -1.59 and a beta of 1.40.

Can-Fite BioPharma (NYSE:CANF) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.20 million. As a group, equities research analysts forecast that Can-Fite BioPharma will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC bought a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned approximately 0.57% of Can-Fite BioPharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.